Order Code SP5TS Septin-5 Antibody, Tissue Immunofluorescence Titer, Serum
Specimen Required
Only orderable as a reflex. For more information see MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum.
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Useful For
Detecting septin-5 IgG in serum specimens
Reporting an end titer result from serum specimens
Testing Algorithm
If the indirect immunofluorescence pattern suggests septin-5, then septin-5 antibody cell-binding assay and this test will be performed at an additional charge.
Method Name
Only orderable as a reflex. For more information see MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum.
Indirect Immunofluorescence Assay (IFA)
Reporting Name
Septin-5 IFA Titer, SSpecimen Type
SerumSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Serum | Refrigerated (preferred) | 28 days | |
Frozen | 28 days | ||
Ambient | 72 hours |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Reference Values
Only orderable as a reflex. For more information see MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum.
<1:240
Method Description
The patient's sample is tested by a standardized immunofluorescence assay (IFA) that uses a composite frozen section of mouse cerebellum, kidney, and gut tissues. After incubation with sample and washing, fluorescein-conjugated goat-antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Samples that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated to an endpoint. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption.(Honorat JA, Komorowski L, Josephs KA, et al: IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 2017 Jul 18;4(5):e385. doi: 10.1212/NXI.0000000000000385)
Day(s) Performed
Monday through Sunday
Performing Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
86256